In preclinical models, the potent cytolytic activity of CVA21 against numerous tumor cells that express ICAM-1 and DAF, and the capability to induce immunogenic cell death that can initiate systemic anti-tumor immune responses, have been shown. The gene discussed is CD55; the disease is neoplasm.